Wegovy and Other Weight Loss Drugs Available in the UK

The biggest misconception: if it contains semaglutide, it must be the same thing

Perhaps the most common assumption people arrive with is this: Ozempic and Wegovy are both semaglutide, so surely they're the same drug doing the same job. It's a reasonable read of the situation, and it's worth letting go of gently, because the licence is what changes everything.

Ozempic is semaglutide, yes. Rybelsus is oral semaglutide. But both are licensed by the MHRA for type 2 diabetes management, not for weight loss. Wegovy uses the same molecule but holds a separate, specific licence for weight management in adults, and it's the formulation and regulatory status that determine what a prescriber can lawfully offer for which condition. The distinction between Ozempic and Wegovy catches a lot of people out, partly because the names circulate together in conversation and online. A prescriber offering Ozempic for weight loss outside of a diabetes diagnosis would be operating outside that drug's licence, which is exactly why it matters which medicine you're actually being assessed for.

Saxenda (liraglutide) is also a GLP-1 receptor agonist with a UK weight management licence, though it requires daily injections rather than weekly, and it works through a single receptor pathway. It was significant when it launched, but newer options have largely moved the clinical conversation on. If you're trying to get your bearings, reading about weight loss drugs like Wegovy can help clarify where each medicine sits and how they compare before you speak to a prescriber. The landscape of licensed weight loss drugs has changed substantially since 2023.

How Wegovy and Mounjaro differ, and why it's a clinical question, not a ranking

Wegovy (the semaglutide injection) activates the GLP-1 receptor, which is involved in appetite signalling and slowing gastric emptying. In the STEP 1 trial, participants lost an average of around 15% of body weight over 68 weeks at the 2.4mg maintenance dose, as reported in the New England Journal of Medicine. A higher 7.2mg dose received MHRA approval in early 2026 and produced average losses of around 20.7% over 72 weeks in trials, narrowing the gap with tirzepatide considerably.

Mounjaro (tirzepatide) works differently: it activates both GLP-1 and GIP receptors, making it the only dual-agonist weight loss medicine licensed in the UK. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide 2.4mg in adults with obesity. NICE recommended tirzepatide for NHS use in December 2024 (TA1026), subject to specific eligibility criteria. You can read about how semaglutide works in more detail if the mechanism is relevant to a conversation you're having with a clinician.

Which option suits any individual depends on their medical history, other medicines they take, whether they have type 2 diabetes, and how they respond to treatment. That's genuinely a clinical judgement. The numbers from trials are a useful starting point; they aren't a prescription.

Wegovy tablets: the newest option, and what's known so far

On 11 June 2026, the MHRA approved oral semaglutide (Wegovy tablets) as the first GLP-1 medicine licensed for weight management that doesn't require an injection. The UK was the first country in Europe to grant this approval. The active ingredient is the same as the injection, but the tablet is taken once daily in the morning on an empty stomach, with a small amount of plain water, waiting at least 30 minutes before food or other medicines.

The dosing schedule runs from 1.5mg up to a 25mg maintenance dose, escalating through 4mg and 9mg with at least a month at each level. In the OASIS 4 phase 3 trial, participants lost an average of around 13.6% of body weight over 64 weeks compared with about 2.4% on placebo. Among those who adhered fully to the protocol, the average was closer to 17%, though that figure applies specifically to the fully-adherent group, not to participants overall.

The absence of refrigeration is a practical difference from the injections: room-temperature storage makes the tablet considerably easier to manage for people who travel or who were put off by the injection route. For a fuller picture of what Wegovy treatment involves, including both the injection and tablet options, that page covers the practical detail. If cost is part of your thinking, the Wegovy pricing page sets out what private treatment typically involves and what any quoted price should include. The FAQs are also worth a read if you have questions about switching between formats.

NHS access versus private prescription: where each medicine sits

Access to these medicines on the NHS follows eligibility criteria set by NICE and NHS England, and the rollout is phased. For tirzepatide, the current cohort requires a BMI of 40 or above alongside four or more specific weight-related conditions. Cohort 2, covering BMI 35–39.9 with four or more conditions, was activated in June 2026. Wegovy is available on the NHS via specialist weight management services under NICE TA875, though waiting lists in many areas are long. The NICE appraisal of tirzepatide (TA1026) and associated NHS England guidance set out the full eligibility framework if you want to check the detail yourself.

Private prescription is the route for people who don't meet NHS criteria, prefer not to wait, or are considering the Wegovy tablet (which has no NICE appraisal yet and is not available on the NHS at launch). A private prescription still requires a genuine clinical assessment. The prescriber reviews your answers, your weight, and your health background before anything is approved. For an overview of the treatment options available privately, that page covers both medicines in plain terms.

If you'd like to understand which of these options might be appropriate for your situation, speaking to our prescribers through a free consultation is the place to start. A clinician reviews every consultation personally (the same day, on working days) and will tell you honestly what they can and can't offer.